Prosecution Insights
Prosecution Insights
10 pending office actions • 9 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (40%) |
| §102 only | 3 (30%) |
| No statute on record | 3 (30%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FETTEROLF, BRANDON J | 1 | 49.5% | +14.6% |
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.0% |
| GRIZER, CASSANDRA SENN | 1 | 100.0% | +0.0% |
| STOICA, ELLY GERALD | 1 | 66.5% | +22.9% |
| CRAIGO, BAHAR ALAWI | 1 | 46.9% | +27.0% |
| BEANE, RANDALL L | 1 | 32.5% | +37.8% |
| BOWLES, DAVID PAUL | 1 | 75.0% | +17.5% |
| PETERS, ALEC JON | 1 | 68.6% | +61.7% |
| LEONARD, ARTHUR S | 1 | 50.5% | +50.7% |
| MATALKAH, FATIMAH KHALAF | 1 | 56.3% | +11.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18271901 | REPLICATION-COMPETENT ADENOVIRUS TYPE 4 SARS-COV-2 VACCINES AND THEIR USE | GRIZER, CASSANDRA SENN | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17346630 | METHODS TO ELIMINATE CANCER STEM CELLS BY TARGETING CD47 | MATALKAH, FATIMAH KHALAF | 51d overdue |
| 18318588 | USES OF MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS | STOICA, ELLY GERALD | 46d overdue |
| 17783171 | ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF | PETERS, ALEC JON | 46d overdue |
| 18032132 | HIGH CONCENTRATION METHYLCOBALAMIN OR COMBINATION OF METHYL- AND HYDROXY-COBALAMIN FOR THE TREATMENT OF COBALAMIN C DEFICIENCY DISORDERS | CRAIGO, BAHAR ALAWI | 44d overdue |
| 17674378 | INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY | LEONARD, ARTHUR S | 23d overdue |
| 18053308 | ANTISENSE THERAPEUTICS FOR BETACORONAVIRUS TREATMENT | BEANE, RANDALL L | 10d overdue |
| 17923394 | ABERRANT POST-TRANSLATIONAL MODIFICATIONS (PTMS) IN METHYL- AND PROPIONIC ACIDEMIA AND A MUTANT SIRTUIN (SIRT) TO METABOLIZE PTMS | BOWLES, DAVID PAUL | 13d |
| 18568738 | COMPOUNDS THAT BIND NON-CANONICAL G-QUADRUPLEX STRUCTURES AND METHODS OF MAKING AND USING THE SAME | FETTEROLF, BRANDON J | 16d |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| 1626 | 1 |
| 1625 | 1 |
| 1672 | 1 |
| 1647 | 1 |
| 1699 | 1 |
| 1641 | 1 |
| 1631 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18568738 | COMPOUNDS THAT BIND NON-CANONICAL G-QUADRUPLEX STRUCTURES AND METHODS OF MAKING AND USING THE SAME | FETTEROLF, BRANDON J | 1626 | §102 | Non-Final OA | 16d | Pending | Dec 08, 2023 |
| 18288318 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | SEAMAN, D MARGARET M | 1625 | §102 | Non-Final OA | 1d overdue | Pending | Oct 25, 2023 |
| 18271901 | REPLICATION-COMPETENT ADENOVIRUS TYPE 4 SARS-COV-2 VACCINES AND THEIR USE | GRIZER, CASSANDRA SENN | 1672 | §103 | Non-Final OA | 34d | Pending | Jul 12, 2023 |
| 18318588 | USES OF MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS | STOICA, ELLY GERALD | 1647 | Other | Non-Final OA | 46d overdue | Pending | May 16, 2023 |
| 18032132 | HIGH CONCENTRATION METHYLCOBALAMIN OR COMBINATION OF METHYL- AND HYDROXY-COBALAMIN FOR THE TREATMENT OF COBALAMIN C DEFICIENCY DISORDERS | CRAIGO, BAHAR ALAWI | 1699 | §103 | Non-Final OA | 44d overdue | Pending | Apr 14, 2023 |
| 18053308 | ANTISENSE THERAPEUTICS FOR BETACORONAVIRUS TREATMENT | BEANE, RANDALL L | 1654 | Other | Non-Final OA | 10d overdue | Pending | Nov 07, 2022 |
| 17923394 | ABERRANT POST-TRANSLATIONAL MODIFICATIONS (PTMS) IN METHYL- AND PROPIONIC ACIDEMIA AND A MUTANT SIRTUIN (SIRT) TO METABOLIZE PTMS | BOWLES, DAVID PAUL | 1654 | §103 | Non-Final OA | 13d | Pending | Nov 04, 2022 |
| 17783171 | ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF | PETERS, ALEC JON | 1641 | Other | Final Rejection | 46d overdue | Pending | Jun 07, 2022 |
| 17674378 | INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY | LEONARD, ARTHUR S | 1631 | §103 | Final Rejection | 23d overdue | Pending | Feb 17, 2022 |
| 17346630 | METHODS TO ELIMINATE CANCER STEM CELLS BY TARGETING CD47 | MATALKAH, FATIMAH KHALAF | 1638 | §102 | Final Rejection | 51d overdue | Pending | Jun 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial